Eli Lilly and Company (NYSE:LLY): Closing price $49.22
Lilly has prevailed in a United Kingdom patent lawsuit against a Johnson & Johnson unit regarding a potential treatment for Alzheimer’s disease. Judge Richard Arnold said in a ruling in London on Tuesday that a patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development division is not valid. Both firms are working on treatments that target the accumulation of plaque in patients’ brains, which is linked to the condition. Companies developing treatments for Alzheimer’s are vying to be first to enter what could be a $20-billion market, according to a report released in 2012 by Deutsche Bank analysts. The United States spokesman for Janssen, Greg Panico, wrote in an e-mail that the unit is “disappointed by the outcome of this case, and we are considering our options.”
Pozen (NASDAQ:POZN): Closing price $4.90
Pzen has presented a post-hoc evaluation of diabetic subpopulation results from two Phase 3 PA32540 (325 mg enteric-coated (EC) aspirin / 40 mg immediate-release omeprazole) studies at the American Diabetes Associations 73rd Scientific Session. Close to 40 percent of patients in the Phase 3 studies had diabetes and were on aspirin (325 mg) for secondary prevention of cardiovascular events. In this subpopulation of four hundred patients, PA32540 was linked with a significantly lower rate of endoscopic gastroduodenal ulcers, versus taking aspirin alone.
Teleflex Incorporated (NYSE:TFX): Closing price $75.84
The provider of medical devices for critical care and surgery said that it was recently awarded a new agreement from HealthTrust for its complete line of LMA Laryngeal Masks. Healthtrust supplies healthcare organizations with solutions for total cost management, among which includes group purchasing.
Zogenix (NASDAQ:ZGNX): Closing price $1.79
In commemoration of National Migraine Awareness Month, and in recognition of the sizable unmet needs of migraine sufferers, Zogenix is debuting a new and enhanced Sumavel DosePro Migraine Toolbox in support of patient education and empowerment. The Migraine Toolbox exhibits the importance of having the appropriate medication on hand in the patient’s “treatment toolbox,” so as to address the specific migraine attack the patient is experiencing.